We are live on ! Find out more
PRGO icon

Perrigo

13.48 USD
-0.06
0.44%
At close Updated Sep 17, 4:00 PM EDT
Pre-market
After hours
13.55
+0.07
0.52%
1 day
-0.44%
5 days
-0.66%
1 month
5.15%
3 months
32.68%
6 months
30.87%
Year to date
-2.95%
1 year
-36.2%
5 years
-69.32%
10 years
-85.55%
 

About: Perrigo is a pure-play consumer healthcare product manufacturer and distributor. In North America (two-thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. It plays in a number of over-the-counter categories including pain, skincare, women's health, and nutrition. Perrigo also competes in Europe, Australia, and parts of Asia, where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.

Employees: 8,100

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 63.2%
Neutral 36.8%
Negative 0%
Positive
Zacks Investment Research
13 days ago
Perrigo (PRGO) Up 13.8% Since Last Earnings Report: Can It Continue?
Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock?
Perrigo (PRGO) Up 13.8% Since Last Earnings Report: Can It Continue?
Neutral
PRNewsWire
21 days ago
Perrigo to Attend the Barclays Global Consumer Conference
DUBLIN, Aug. 27, 2026 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of consumer self-care products, today announced that Interim President and CEO Albert Manzone and CFO Eduardo Bezerra are scheduled to participate in investor meetings at the Barclays Global Consumer Conference on Thursday, September 10th, 2026.  About Perrigo    Perrigo Company plc is a leading pure-play self-care company with over a century of experience in providing high-quality health and wellness solutions to consumers primarily in North America and Europe.
Perrigo to Attend the Barclays Global Consumer Conference
Positive
Zacks Investment Research
22 days ago
PRGO or NEOG: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical - Products stocks have likely encountered both Perrigo (PRGO) and Neogen (NEOG). But which of these two stocks is more attractive to value investors?
PRGO or NEOG: Which Is the Better Value Stock Right Now?
Positive
Zacks Investment Research
22 days ago
Should Value Investors Buy Perrigo (PRGO) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Should Value Investors Buy Perrigo (PRGO) Stock?
Positive
Benzinga
23 days ago
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
Positive
Seeking Alpha
24 days ago
My Top 5 Dividend Picks For August
I present my August top 5 dividend picks: PRGO, MZTI, NEE, TROW, and VICI, all rated Buy or Strong Buy for rising income and appreciation. Each pick trades at a significant discount to fair value (average 21.5%), offering an expected 5-year compound annual total return of ~12.5% and a 5.22% yield. PRGO, MZTI, and VICI stand out for deep undervaluation and robust dividend growth, with VICI offering a projected 15.8% CAGR and strong inflation-linked lease structures.
My Top 5 Dividend Picks For August
Positive
Seeking Alpha
1 month ago
Perrigo: The Rebound Is Just Getting Started
Perrigo Company remains substantially undervalued, with a Buy rating justified by strong income and growth potential. Recent quarterly EPS and revenue beats, coupled with market share gains, signal improving fundamentals despite a soft OTC market. Management's focus on cost control, debt reduction, and dividend growth underpins a compelling 16–21% expected annual total return.
Perrigo: The Rebound Is Just Getting Started
Positive
Zacks Investment Research
1 month ago
PRGO vs. NEOG: Which Stock Is the Better Value Option?
Investors with an interest in Medical - Products stocks have likely encountered both Perrigo (PRGO) and Neogen (NEOG). But which of these two companies is the best option for those looking for undervalued stocks?
PRGO vs. NEOG: Which Stock Is the Better Value Option?
Positive
Zacks Investment Research
1 month ago
Are Investors Undervaluing Perrigo (PRGO) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Are Investors Undervaluing Perrigo (PRGO) Right Now?
Positive
MarketBeat
1 month ago
Perrigo Q2 Earnings Call Highlights
Perrigo NYSE: PRGO reported second-quarter 2026 results that exceeded its internal earnings expectations, while sales declined amid soft consumer self-care categories, retailer inventory reductions and a slower start to seasonal demand. The company maintained its full-year outlook, citing improving category trends, market-share gains and expected second-half contributions from innovation, distribution and demand-generation efforts.
Perrigo Q2 Earnings Call Highlights
Price charts implemented using Lightweight Charts™